Literature DB >> 31081972

Lidocine potentiates the cytotoxicity of 5-fluorouracil to choriocarcinoma cells by downregulating ABC transport proteins expression.

Xue Zhang1, Wenwen Pang1, Hong Liu1, Juan Wang1.   

Abstract

Choriocarcinoma is a gestational trophoblastic cancer, which often occurs in the first 3 months of pregnancy. 5-Fluorouracil (5-Fu) is the widely used chemotherapeutic drug for choriocarcinoma but limited by drug resistance. Lidocaine, an aminamide-type anesthetic, shows potential anticancer and chemosensitization effects in recent years. Herein, we tested the possible chemosensitization activity of lidocaine on the cytotoxicity of 5-Fu in choriocarcinoma cells. Viabilities and apoptosis of choriocarcinoma JEG-3 and JAR cells after lidocaine and/or 5-Fu treatment were detected using Cell Counting Kit-8 assay, annexin V-FITC/PI (fluorescein isothiocyanate/propidium iodide) staining and Western blot analysis, respectively. Quantitative reverse transcription polymerase chain reaction was done to measure breast cancer resistance protein (ABCG2) messenger RNA level. Western blot analysis was carried out to detect ABCG2, P-glycoprotein (P-gp), MRP1, and MRP2 protein levels. pEX-ABCG2 was transfected to elevate ABCG2 level. Then, the influence of ABCG2 on lidocaine + 5-Fu-caused cell viability loss, apoptosis, and inactivation of PI3K/AKT pathway were analyzed. We found that lidocaine in low concentration had no significant cytotoxicity to JEG-3 and JAR cells, but stimulated cell apoptosis in high concentration. Moreover, lidocaine potentiated the cytotoxicity of 5-Fu to JEG-3 and JAR cells through decreasing viability and increasing apoptosis. Lidocaine treatment reduced the ABCG2, P-gp, MRP1, and MRP2 protein levels in cells. Overexpression of ABCG2 reversed the synergistic effects of lidocaine + 5-Fu on JEG-3 and JAR cell viability and apoptosis, as well as PI3K/AKT pathway. Our research verified that lidocaine potentiated the cytotoxicity of 5-Fu to choriocarcinoma cells by downregulating ATP-binding cassette (ABC) transport proteins expression.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  5-fluorouracil; PI3K/AKT signaling pathway; breast cancer resistance protein; choriocarcinoma; lidocaine

Year:  2019        PMID: 31081972     DOI: 10.1002/jcb.28913

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  8 in total

Review 1.  Local anesthetics and immunotherapy: a novel combination to fight cancer.

Authors:  Lucillia Bezu; Oliver Kepp; Guido Kroemer
Journal:  Semin Immunopathol       Date:  2022-08-31       Impact factor: 11.759

Review 2.  The Use of Intravenous Lidocaine in Perioperative Medicine: Anaesthetic, Analgesic and Immune-Modulatory Aspects.

Authors:  Ingrid Wing-Sum Lee; Stefan Schraag
Journal:  J Clin Med       Date:  2022-06-20       Impact factor: 4.964

Review 3.  Direct Cytotoxic and Indirect, Immune-Mediated Effects of Local Anesthetics Against Cancer.

Authors:  Alejandra Wu Chuang; Oliver Kepp; Guido Kroemer; Lucillia Bezu
Journal:  Front Oncol       Date:  2022-01-14       Impact factor: 6.244

Review 4.  Impact of local anesthetics on epigenetics in cancer.

Authors:  Lucillia Bezu; Oliver Kepp; Guido Kroemer
Journal:  Front Oncol       Date:  2022-08-30       Impact factor: 5.738

Review 5.  Local Anesthetic Lidocaine and Cancer: Insight Into Tumor Progression and Recurrence.

Authors:  Caihui Zhang; Cuiyu Xie; Yao Lu
Journal:  Front Oncol       Date:  2021-06-24       Impact factor: 6.244

6.  Quantitative Proteomic Profiling Identifies SOX8 as Novel Regulator of Drug Resistance in Gestational Trophoblastic Neoplasia.

Authors:  Fu Jun; Zheng Peng; Yi Zhang; Dazun Shi
Journal:  Front Oncol       Date:  2020-04-28       Impact factor: 6.244

7.  Up-regulation of FAT4 enhances the chemosensitivity of colorectal cancer cells treated by 5-FU.

Authors:  Qianyuan Li; Xiukou Zhou; Zhengyu Fang; Zhiyun Pan; Huamiao Zhou
Journal:  Transl Cancer Res       Date:  2020-01       Impact factor: 1.241

8.  Insulin reverses choriocarcinoma 5- fluorouracil resistance.

Authors:  Ying Shan; Yanyi Li; Hongyu Han; Cui Jiang; Hu Zhang; Jiachang Hu; Huanmei Sun; Jianglong Zhu
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.